Achillion Pharmaceuticals, Inc. ACHN announced that it has started a phase I study on its first orally administered small molecule complement factor D inhibitor, ACH-4471. The randomized, ...
WALTHAM, Mass., May 26, 2022 /PRNewswire/ -- Q32 Bio, a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced that dosing has been ...
The FDA fully approved iptacopan (Fabhalta) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression, drugmaker Novartis announced on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results